Post by OncoDaily Biotech

Name: AbbVie and Genmab reported that the Phase 3 EPCORE DLBCL-4 trial hit its primary endpoint. In second
Uploaded: 2026-07-04T15:49:10.773Z
Channel: OncoDaily Biotech
Description: AbbVie and Genmab reported that the Phase 3 EPCORE DLBCL-4 trial hit its primary endpoint. In second-line relapsed/refractory DLBCL, epcoritamab plus lenalidomide cut the risk of progression or death

2,160 followers

AbbVie and Genmab reported that the Phase 3 EPCORE DLBCL-4 trial hit its primary endpoint. In second-line relapsed/refractory DLBCL, epcoritamab plus lenalidomide cut the risk of progression or death by 60% versus R-GemOx (HR 0.40; p<0.0001) — from a fixed-duration, chemo-free regimen. Our new analysis unpacks what this means for a genuinely hard-to-treat population (post-transplant relapse, CAR-T–ineligible), how the chemo-free design happens to sidestep the very issues that tripped up Roche's STARGLO at the FDA, and what still has to land before a second-line label. When the cutting edge medicine is, by design, hard to scale, are we going to build the system around the breakthrough? or the patient that can't get it? Leave you answer in the comments below 👇 Read the full breakdown: https://lnkd.in/g64FRDgi #DLBCL #Lymphoma #Oncology #Biotech #Epcoritamab #Hematology

Video Content